Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 7/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 7/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.44 |
| ▸ | CHRNB3 | Q05901 | 5/20 | 0.44 |
| ▸ | CHRNA6 | Q15825 | 5/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12076556 | 0.88 | HPGD (0.50) | HPGDALDH1A1TSHRHTTCHRNB2 | |
| SCHEMBL12760600 | 0.88 | HPGD (0.50) | HPGDALDH1A1TSHRHTTCHRNB2 | |
| SCHEMBL2181877 | 0.79 | HPGD (0.75) | HPGDALDH1A1TSHRHTTCHRNB2 | |
| SCHEMBL3123799 | 0.78 | ALDH1A1 (0.36) | HPGDALDH1A1HTTLMNA | |
| SCHEMBL478663 | 0.78 | ALDH1A1 (0.39) | HPGDALDH1A1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL478305 | 0.77 | MEN1 (0.46) | HPGDALDH1A1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL20632867 | 0.76 | HPGD (0.57) | HPGDALDH1A1TSHRHTTCHRNB2 | |
| SCHEMBL22269818 | 0.76 | HPGD (0.57) | HPGDALDH1A1TSHRHTTCHRNB2 | |
| SCHEMBL478741 | 0.76 | ALDH1A1 (0.58) | HPGDALDH1A1TSHRHTTLMNA | |
| SCHEMBL14275803 | 0.76 | HPGD (0.57) | HPGDALDH1A1TSHRHTTCHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324199-B2 | Pyridazine derivatives as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | claimed |
| EP-2265601-B1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-02-01 | — | — | EP | claimed |
| CN-102026996-A | Pyridazine derivatives as factor XIA inhibitors | BRISTOL MYERS SQUIBB CO | 2011-04-20 | — | — | CN | claimed |
| US-20110021492-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-27 | — | — | US | claimed |
| EP-2265601-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2010-12-29 | — | — | EP | claimed |
| WO-2009114677-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-17 | — | — | WO | claimed |
| US-8324199-B2 | Pyridazine derivatives as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | disclosed |
| EP-2265601-B1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-02-01 | — | — | EP | disclosed |
| CN-102026996-A | Pyridazine derivatives as factor XIA inhibitors | BRISTOL MYERS SQUIBB CO | 2011-04-20 | — | — | CN | disclosed |
| US-20110021492-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-27 | — | — | US | disclosed |
| EP-2265601-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009114677-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021492-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | F11, F12, TFPI2 | HPGD 1220/4885ALDH1A1 2830/4885TSHR 1896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.